Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01019590 | Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg | PHASE1 | COMPLETED | 36 | — | — | Nov 1, 2006 | Nov 1, 2006 | Apr 23, 2024 | 1 | United States |
| NCT01020214 | Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg | PHASE1 | COMPLETED | 36 | — | — | Nov 1, 2006 | Nov 1, 2006 | Apr 23, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Benicar HCT ® Tablets 40 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg | DRUG | - |
| Benicar HCT ® Tablets 40 mg/25 mg | DRUG | - |
| Benicar HCT® Tablets 40 mg/25 mg | DRUG | - |
Inclusion Criteria: * healthy, adult subjects, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days of start of study * received any investigational product...